ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Diagnostic Center For Disease: Prostate Biopsy Spreads Prostate Cancer Cells
Breaking news from the
Diagnostic Center for Disease(TM) in Sarasota, Florida, identifies a
previously underestimated risk that routine prostate biopsy performed to
evaluate for prostate cancer spreads cancer cells and may be the reason
that men have a recurrence of disease many years after the prostate was
removed successfully with clear surgical margins. Traditionally, an
ultrasound and prostate biopsy is commonly recommended and performed by
Urologists when a patient presents with a prostate specific antigen (PSA)
of 2.5 ng/ml or above. Men have been told for years that the procedure is
safe and the only way to diagnose prostate cancer. While this paradigm
represents the current standard, the system exposes far too many men to
needless biopsies; as the number one reason PSA rises is prostatitis, not
prostate cancer. Still other men may have a small cancer that is missed
based on the inability of this standard procedure to target a suspected
lesion in question (sampling error). Regardless of the rationale for a
biopsy, all men suffer the potential risk for bleeding, scarring, infection
or sepsis and needless intrusion that has reportedly resulted in impotency
and/or incontinence in some patients. A more important issue that is often
not discussed between physician and patient involves the possibility of
"needle tracking", the very real possibility of spreading cancer cells
beyond the prostate when a biopsy is performed. An extensive review of the
literature confirms that once a needle penetrates the capsule of an organ,
a phenomenon called "needle tracking" takes place. When the needle is
withdrawn from the targeted organ, the chance of spreading cancer cells
(when encountered) establishes itself, and every puncture of the prostate
adds to this risk. Despite the significance of this risk to the patient,
physicians generally fail to acknowledge a process that allows cells to lie
dormant or incubate for up to 10 years or more regardless of the treatment
rendered. In a 2 billion dollar prostate biopsy industry, the phenomenon of
"needle tracking" takes place approximately 20-30 percent of the time. This
coincides with the frequency that ultrasound and biopsy encounters a
cancer, suggesting that 70- 80 percent of biopsies are performed
unnecessarily.
A recent evaluation of data from patients with a positive MRI-S scan at
the Diagnostic Center for Disease(TM) found 75 percent of biopsies
performed yielded a cancer, allowing men without cancer to avoid a biopsy
procedure. This is a quantum leap from the blind biopsy approach enabling
the potential savings of millions of dollars to the healthcare industry.
The secret to success involved the use of a 3.0 Tesla Magnetic Resonance
Imaging Spectroscopy scan (MRI -S) which predicted and confirmed the
presence of prostate cancer. This technology, featured at the Diagnostic
Center for Disease(TM), represents the most sensitive and specific
diagnostic modality for the prostate evaluation in the world, replacing
substandard scanning procedures like PET scan, CAT scan and Prostascint
scans. The MRI -S at 3.0 Tesla allows imaging of the entire prostate,
thereby, creating a roadmap; thereby, allowing selective targeting of
specific areas of interest for biopsy when indicated. In many cases, a
biopsy is not recommended at all as no cancer is found. Furthermore, this
methodology allows for fewer biopsies versus the "shot in the dark" 12-24
core biopsy approach or the saturation biopsy, thereby minimizing risk to
the patient in the event a lesion is isolated, a specific protocol is
implemented to prevent cells from proliferating; in effect, causing cells
to become weakened, disabled and die through a process called apoptosis.
This protocol is unique to the Diagnostic Center for Disease(TM). The
Center's success with the MRI-S scan is further magnified by de-selecting
men with an elevated PSA who don't have prostate cancer but rather have
prostatitis, a non-bacterial inflammatory disease; the primary reason PSA
rises. In these instances, the Center's physicians encourage the use of an
internationally patented formula to decrease and/or normalize the PSA in
patients without evidence of prostate cancer. While the literature suggests
that all men will get prostate cancer if they live long enough, there is no
reason to accelerate the process or undergo a premature biopsy, where the
patient assumes all of the risk. To reiterate, a 3.0 Tesla MRI-S scan
creates a roadmap to guide targeted biopsies to the specific region of
interest while avoiding areas that fail to exhibit the "fingerprint" of
disease. At the Diagnostic Center for Disease(TM), physicians recognize
that better imaging enables an improved opportunity to diagnose disease
while ensuring a better, more predictable outcome.
A recent case of a 71-year-old man illustrates the benefit of the 3.0
Telsa MRI -S. In 1997, his PSA was measured at 3.7 ng/ml. Presumed to be
normal, the PSA was not tested again until 2001, when it was 7.2 ng/ml-well
above the 4.0 ng/ml level of concern. A biopsy using a traditional
ultrasound evaluation resulted in eight negative cores. The following year,
the patient's PSA was 11.5 ng/ml. This time, in addition to the gray scale
ultrasound, physicians used color flow doppler (CFD) to isolate areas of
blood flow, important to prostate cancer growth. Despite the use of CFD to
target areas of interest, the biopsy results were once again negative.
Frustrated, the patient turned to the 3.0 T MRI -S scan. Despite a lack of
evidence for cancer on the physical examination of the prostate, the scan
located a discreet, well- defined 4.5 mm lesion deep within the peripheral
zone of the mid-prostate on the left side. Subsequently, five targeted
biopsies identified an aggressive cancer. Having established that the
cancer was organ confined with no evidence of spread to the surrounding
tissue, the patient was now able to focus on viable treatment options.
"Men who have an elevated PSA and want to avoid an unnecessary prostate
biopsy now have an alternative to a blind biopsy," states Ronald Wheeler,
M.D., the Medical Director at the center. Additionally, men who want a
second opinion when the previous biopsy was negative can now go to the only
imaging center in the world that is dedicated exclusively to the diagnosis
and treatment of prostate disease.
Diagnostic Center for Disease
http://www.mrisusa.com
Centrul de diagnostic pentru boala: biopsie de prostatã Pariuri cu handicap celulele cancerului de prostatã - Diagnostic Center For Disease: Prostate Biopsy Spreads Prostate Cancer Cells - articole medicale engleza - startsanatate